Navigation Links
Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
Date:6/2/2009

SAN RAMON, Calif., June 2 /PRNewswire/ -- BioGenex, a developer of innovative instruments and reagents for automated slide based staining systems for molecular diagnostics, announced today that Abbott has entered into a definitive agreement to extend the technology co-development and distribution agreement to market the Xmatrx(R) platform for the automation of Abbott's extensive FISH product line. Under the terms of the agreement Abbott customers will have the option to run IHC and ISH on the Xmatrx and BioGenex customers to run FISH on their system.

"We are extremely pleased that Abbott has chosen to renew our relationship with this multi-year extension of our original agreement. This is a testament to the truly unique capabilities of the Xmatrx(R) platform, which allows for the automation of advanced molecular staining assays, from Microtome to Microscope," said Dr. Krishan Kalra, CEO, BioGenex. "We look forward to furthering our partnership and delivering solutions that can further accelerate the adoption of molecular medicine approaches from drug discovery through clinical diagnostics."

The Xmatrx(R) platform allows for the walk-away automation of the entire FISH assay workflow, from specimen pretreatment to final cover-slipping and is designed for optimal results with Abbott Molecular AutoFISH(TM) reagents and FISH technology.

The Xmatrx will be co-branded and marketed under a co-exclusive distribution agreement which calls for both parties to collaborate further in aiding adoption of FISH, IHC and ISH as primary tools in the emerging field of molecular diagnostics and personalized medicine. Under the terms of the agreement BioGenex will receive a multi-year minimum volume commitment from Abbott.

About Xmatrx

The Xmatrx(R) is an integrated system consisting of a flexible intelligent platform capable of full automation from "Microtome to Microscope" for any slide based assay, and specially formulated and optimized reagents, including primary antibodies, detection kits and appropriate consumables. The outcome of this approach provides a total solution capable of delivering reproducible and consistent results for IHC, ISH and FISH applications from baking through final cover-slipping.

About BioGenex

BioGenex provides products and services that support the molecular medicine testing continuum, from basic discovery, through translational research to IVD diagnostic testing. The company offers innovative instrument platforms and a broad range of reagents to standardize and bring workflow improvements to slide based assays; delivering solutions that provide the answers to the fundamental questions that lie at the heart of complex diseases. With a strong intellectual property portfolio the company intends to be a central player in the emerging molecular diagnostic and personalized medicine market place. The company is headquartered in San Ramon, California. For further information log on to www.biogenex.com.


'/>"/>
SOURCE BioGenex
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Abbott Named One of the Top 10 Companies for Scientists
2. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
3. Abbott to Present at Barclays Global Healthcare Conference
4. Abbott Employee Giving Sets New Records for Employee Participation and Total Donations
5. Abbott Announces 11 Percent Increase in Quarterly Dividend
6. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
7. Abbott Announces Earnings Guidance for 2009
8. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
9. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
10. Abbotts XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
11. Abbott Hosts Conference Call for Third-Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... , ... January 11, 2017 , ... Back pain relief ... No Shots and No Surgery for positive back pain relief for WAR members. , ... results worldwide and could be life changing for millions suffering from chronic back pain. ...
(Date:1/11/2017)... , PITTSBURGH and BENGALURU, ... N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: ... and Drug Administration (FDA) has accepted Mylan,s biologics license ... filing through the 351(k) pathway. This product is a ... treat certain HER2-positive breast cancers. The anticipated FDA goal ...
(Date:1/11/2017)... 2017  GenVec, Inc. (NASDAQ: GNVC ... that its chief scientific officer, Douglas E. ... platform for translational development of innovative gene and ... upcoming Phacilitate Cell & Gene Therapy World 2017 ... Dr. Brough,s presentation will highlight the utility of ...
(Date:1/11/2017)... ... January 11, 2017 , ... KBioBox llc ... with Poseida Therapeutics Inc, the San Diego based specialist in gene and cell ... KBioBox in order to harness KBioBox’s powerful BioEngine Algorithms which do not compromise ...
Breaking Biology Technology:
(Date:12/15/2016)... ... Research and Markets has announced the addition of the "Global ... The report forecasts the global military biometrics market to grow at a ... has been prepared based on an in-depth market analysis with inputs from ... over the coming years. The report also includes a discussion of the ...
(Date:12/12/2016)... CLEVELAND , Dec. 12, 2016  Researchers ... commercial possibilities for graphene by combining the material ... a highly sensitive pressure detector able to sense ... of a small spider.  The ... and can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... TEL AVIV, Israel , December 7, 2016 ... year with the expansion of its patent portfolio, which grew to over ... , , ... led by its recently filed patent entitled " System, Device, ... which covers technology that enables device makers to forego costly hardware components ...
Breaking Biology News(10 mins):